At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 31 enrolled
Drug / intervention
Luvadaxistat +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate Pharmacodynamic Effects, Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of TAK-831 in Adult Subjects With Schizophrenia
In Brief
A Phase 2 clinical trial evaluating Luvadaxistat and Matching Placebo for Schizophrenia. Completed, enrolled 31 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether luvadaxistat is superior to placebo in improving cerebellar function as measured with the average percentage of conditioned responses during the eyeblink conditioning (EBC) test.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesUnited States
CollaboratorsTakeda
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedDec 2017
Enrollment StartJan 2018
Primary CompletionDec 2020
TodayJul 2026
First PostedDec 2, 2017
Enrollment StartJan 10, 2018
Primary CompletionDec 21, 2020
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 8.6 years ago
Interventions
Luvadaxistatdrug
TAK-831 Tablets.
Matching Placebodrug
Matching Placebo Tablets.